Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
US10167295B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10167295-B2 |
| Application number | US-201514851248-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 11, 2015 |
| Priority date | Mar 15, 2013 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein, inter alia, are methods and compositions for achieving an analgesic effect in subjects in need thereof.
Opening claim text (preview).
What is claimed is: 1. A method of producing sexually dimorphic analgesia in a male subject in need thereof, the method comprising administering to the male subject a therapeutically effective amount of a compound having the formula: or a pharmaceutically acceptable salt thereof; wherein R 4 is hydrogen or methyl; R 5 is —C(O)-L 1 -R 3 ; L 1 is a bond, —CH 2 —, —CH 2 CH 2 —, or —CH 2 CH 2 CH 2 —; and R 3 is (i) an unsubstituted 5-membered heterocyloalkyl; (ii) an unsubstituted 6-membered heterocycloalkyl; (iii) a 5-membered heterocyloalkyl substituted with one or two substituents selected from the group consisting of ═O, halogen, —OH, —NH 2 , —SH, —C(O)OH, —C(O)NH 2 , —CF 3 , —CCl 3 , —CN, —N 3 , an unsubstituted C 1 -C 8 alkyl, and benzyl; or (iv) a 6-membered heterocycloalkyl. 2. The method of claim 1 , wherein R 3 is (i) an unsubstituted 5-membered heterocyloalkyl containing one nitrogen heteroatom; (ii) an unsubstituted 6-membered heterocycloalkyl containing one nitrogen heteroatom; (iii) a 5-membered heterocyloalkyl containing one nitrogen heteroatom and one or two substituents selected from the group consisting of ═O, halogen, —OH, —NH 2 , —SH, —C(O)OH, —C(O)NH 2 , —CF 3 , —CCl 3 , —CN, —N 3 , an unsubstituted C 1 -C 8 alkyl, and a benzyl; or (iv) a 6-membered heterocycloalkyl containing one nitrogen heteroatom and one or two substituents selected from the group consisting of ═O, halogen, —OH, —NH 2 , —SH, —C(O)OH, —C(O)NH 2 , —CF 3 , —CCl 3 , —CN, —N 3 , an unsubstituted C 1 -C 8 alkyl, a benzyl, and an indene moiety. 3. The method of claim 1 , wherein R 3 is a 5-membered heterocyloalkyl containing one nitrogen heteroatom and one or two substituents selected from the group consisting of ═O, —OH, —NH 2 , benzyl, methyl, and ethyl; or a 6-membered heterocycloalkyl containing one nitrogen heteroatom and one or two substituents selected from the group consisting of ═O, —OH, —NH 2 , methyl, ethyl, benzyl, and an indene moiety. 4. The method of claim 1 , wherein the compound is of the formula: 5. The method of claim 4 , wherein the compound is of the formula: 6. The method of claim 5 , wherein the compound is of the formula:
with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title
with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone · CPC title
containing three or more hetero rings · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.